Sugi Predict

Sugi Predict / Compounds / SCHEMBL1148993

SCHEMBL1148993

SCHEMBL1148993

CCOC(=O)C(C)C(=O)CC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SOAT1 P35610 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.43
▸ LMNA P02545 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ ALOX15 P16050 1/20 0.40
▸ MGAM O43451 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ SI P14410 1/20 0.40
▸ MGAM2 Q2M2H8 1/20 0.40
▸ TRPA1 O75762 1/20 0.37
▸ CPB2 Q96IY4 1/20 0.36
▸ PIN1 Q13526 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ CAD P27708 1/20 0.33
▸ MMP8 P22894 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL141446 0.84 ALDH1A1 (0.53) SOAT1ALDH1A1LMNAHSD17B10HPGD
SCHEMBL8800602 0.81 ALDH1A1 (0.50) SOAT1ALDH1A1LMNAHSD17B10HPGD
SCHEMBL28186389 0.81 ALDH1A1 (0.50) SOAT1ALDH1A1LMNAHSD17B10HPGD
Ethane SCHEMBL9181718 0.81 ALDH1A1 (0.50) SOAT1ALDH1A1LMNAHSD17B10HPGD
Ammonia Solution, Strong SCHEMBL28791130 0.81 ALDH1A1 (0.50) SOAT1ALDH1A1LMNAHSD17B10HPGD
SCHEMBL2823198 0.81 ALDH1A1 (0.40) SOAT1ALDH1A1LMNAHSD17B10HPGD
SCHEMBL2553362 0.81 ALDH1A1 (0.50) SOAT1ALDH1A1LMNAHSD17B10HPGD
SCHEMBL4939835 0.81 ALDH1A1 (0.40) SOAT1ALDH1A1LMNAHSD17B10HPGD
SCHEMBL10605963 0.81 HCAR2 (0.38) SOAT1ALDH1A1LMNAHSD17B10HCAR2
SCHEMBL114574 0.80 SMN1; SMN2 (0.41) SOAT1ALDH1A1MGAMGAASI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111808020-B Synthetic method of flometoquin intermediate 湖南速博生物技术有限公司 2020-12-01 — — CN claimed
CN-111808020-A Synthetic method of flometoquin intermediate 湖南速博生物技术有限公司 2020-10-23 — — CN claimed
US-20260125364-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2026-05-07 — — US disclosed
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2024-09-26 — — US disclosed
EP-3468953-B1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE IP DEV LTD (GB) 2024-05-22 — — EP disclosed
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2024-04-23 — — US disclosed
CN-116854578-A Preparation method of sodium valproate process impurity 2-methyl valeric acid 湖南省湘中制药有限公司 2023-10-10 — — CN disclosed
EP-3421462-B1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2023-04-05 — — EP disclosed
CN-107417719-B Application of titanium chelate as reaction catalyst for synthesizing benzyl carbonate or diphenyl carbonate by ester exchange 华东理工大学 2022-11-25 — — CN disclosed
CN-111566088-B Quinoline derivative and preparation method and application thereof 东莞市东阳光农药研发有限公司 2022-07-08 — — CN disclosed
CN-109563043-B Substituted pyridines as inhibitors of DNMT1 葛兰素史密斯克莱知识产权发展有限公司 2022-05-31 — — CN disclosed
US-4515915-A Polyamide acid composition for preparing polyimide KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1985-05-07 — — US disclosed
EP-0114059-A2 Method of preparing a polyamide acid composition for preparing polyimide KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1984-07-25 — — EP disclosed
US-4291036-A Pyrido[1,2-A]pyrimidine derivatives and method of analgesic treatment CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) 1981-09-22 — — US disclosed
US-4219649-A ANALGESICS CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT (HU) 1980-08-26 — — US disclosed
US-4081596-A DIURETIC, SALURETIC, ANTIHYPERTENSIVE, ANTITHROMBOTIC BAYER AKTIENGESELLSCHAFT (DT) 1978-03-28 — — US disclosed
US-4031130-A Aliphatic β-keto esters AGFA-GEVAERT, A.G. (DT) 1977-06-21 — — US disclosed
US-4005215-A DIURETIC BAYER AKTIENGESELLSCHAFT (DT) 1977-01-25 — — US disclosed
US-3978077-A DIURETIC, HYPOTENSIVE, ANTITHROMBOTIC BAYER AKTIENGESELLSCHAFT (GB) 1976-08-31 — — US disclosed
US-3957814-A DIURETICS, SALURETICS, HYPOTENSIVE AGENTS, ANTITHROMBOTIC BAYER AKTIENGESELLSCHAFT (DT) 1976-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125364-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS HTR6, HTR3C, OPRD1 SOAT1 1068/4885ALDH1A1 3129/4885LMNA 2257/4885
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD2, DRD1, HTR1D SOAT1 1855/4885ALDH1A1 3603/4885LMNA 2789/4885
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, HTR1D SOAT1 1855/4885ALDH1A1 3603/4885LMNA 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.